Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accounts Payables (2016 - 2025)

Lisata Therapeutics' Accounts Payables history spans 13 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 20.64% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 20.64%, while the annual FY2025 figure was $1.0 million, 20.64% down from the prior year.
  • Accounts Payables reached $1.0 million in Q4 2025 per LSTA's latest filing, up from $619000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $2.4 million in Q4 2023 to a low of $556000.0 in Q3 2024.
  • Average Accounts Payables over 3 years is $1.1 million, with a median of $900500.0 recorded in 2025.
  • Peak YoY movement for Accounts Payables: tumbled 57.62% in 2024, then grew 11.33% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $2.4 million in 2023, then tumbled by 46.96% to $1.3 million in 2024, then fell by 20.64% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Accounts Payables are $1.0 million (Q4 2025), $619000.0 (Q3 2025), and $782000.0 (Q2 2025).